Ecovyst (ECVT) reported earnings on Thur 31 Oct 24 (b/o)

The company was formerly known as PQ Group Holdings Inc. and changed its name to Ecovyst Inc. in August 2021.

• Sector(s): Basic Materials
• Industry: Specialty Chemicals
• Full Time Employees: 911
• Founded in 1831 
• Headquartered in Malvern, Pennsylvania
• https://www.ecovyst.com

** charts 1 day after earnings **

Day One (DAWN) reported earnings on Wed 30 Oct 24 (a/h)

ticker: DAWN

** charts after earnings **

 

 

BRISBANE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its third quarter 2024 financial results and highlighted recent corporate achievements.

Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue.

Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments.

Program Highlights

• Strong growth in OJEMDA net revenue with $20.1M in the third quarter of 2024, representing a 145% increase over the second quarter of 2024.
• Quarterly prescriptions (TRx) grew to 619 in the third quarter of 2024, representing a 159% increase over the second quarter of 2024.
• Day One expects to dose the first patient in the Phase 1a portion of the Phase 1a/b clinical trial of DAY301 by the end of 2024 or in the first quarter of 2025.
• Day One provided updated duration of response data from the registrational Phase 2 FIREFLY-1 trial investigating tovorafenib in patients with BRAF-altered, relapsed or progressive pLGG. For the 77 patients enrolled on Arm 1, which was the dataset used to assess OJEMDA’s efficacy, the median duration of response is 18 months.
• The pivotal Phase 3 FIREFLY-2/LOGGIC clinical trial evaluating tovorafenib as a front-line therapy in patients aged 6 months to 25 years with pLGG continues to enroll patients in the United States, Canada, Europe, Australia and Asia, with more than 100 sites activated.

Corporate Highlights and Upcoming Milestones

• Day One and Ipsen entered into an exclusive licensing agreement to commercialize tovorafenib outside of the U.S. in July 2024. Under the agreement, Day One received approximately $111 million upfront in cash and equity investment at a premium with up to approximately $350 million in additional launch and sales milestone payments as well as tiered double-digit royalties starting at mid-teens percentage on net sales.
• Day One entered into a definitive agreement for an oversubscribed private placement of its securities for total gross proceeds of approximately $175 million in July 2024.

Long trade : REPL +50% (6/23)

•   Wed 6/5; vol. 950K

 

 

Energizer (ENR) reported earnings on Wed 8 Nov 17 (b/o)

 Energizer Holdings is an American manufacturer of batteries

• Headquarters: St. Louis, MO
• Founded: 1896
• energizerholdings.com
• Div/yield 0.28/2.63

** charts before earnings **

 

** charts after earnings **

Energizer beats by $0.05, beats on revs; guides FY18 EPS in-line; plans to raises dividend 5% next quarter

• Reports Q4 (Sep) earnings of $0.54 per share, $0.05 better than the Capital IQ Consensus of $0.49; revenues rose 7.5% year/year to $465 mln vs the $437.36 mln Capital IQ Consensus. Organic net sales increased 7.5%, due primarily to hurricane activity in the U.S., distribution gains in certain international markets and timing of holiday activity and the favorable impact of pricing initiatives. These items were partially offset by additional investments made during the quarter related to our portfolio optimization. Favorable movement in foreign currencies resulted in increased sales of $0.1 million, or 0.1%.
• Co issues in-line guidance for FY18, sees EPS of $3.00-3.10 vs. $3.04 Capital IQ Consensus Estimate. Net Sales on a reported basis are expected to be up low single digits: Organic net sales are expected to be up low single digits, including lapping the impact of hurricane activity of ~$26 million and lapping distribution in fiscal 2017; Favorable movements in foreign currency are expected to benefit net sales by 1.0% to 1.5% based on current rates. Gross margin rates are expected to be essentially flat with the current year, excluding fiscal 2017 acquisition and integration costs, as improved pricing is offset by increased commodity costs and the repositioning of lithium pricing.
• Dividends are expected to increase 5% beginning in the first quarter of fiscal 2018, subject to Board approval.